Poster

• Achievement of Minimal Symptom Expression in Participants Treated With Efgartigimod in ADAPT+ and ADAPT-SC+
• COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
• Efficacy and Safety of Efgartigimod IV and PH20 SC in gMG: Analysis of AChR-Ab− Participants in ADAPT+/ADAPT-SC+
• Efgartigimod Consistently Improved Health-Related Quality of Life in AChR-Ab+ Participants With gMG in IV and SC Trials
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalised Myasthenia Gravis: Part A of ADAPT NXT
• Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20: Interim Results of the ADAPT-SC+ Trial
• Real world reduction in oral corticosteroid utilization following efgartigimod initiation
• Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
• Steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records
• Subcutaneous Efgartigimod PH20 Demonstrates Improvements in gMG Patients Regardless of Prior Administration Route

Poster

• Achievement of Minimal Symptom Expression in Acetylcholine Receptor Antibody-Positive Participants Treated With Efgartigimod in ADAPT/ADAPT+
• Real-World Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients With Generalized Myasthenia Gravis

Poster

• Exploring the Impact of Non-steroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients with Myasthenia Gravis in the National Veterans Affairs Health
• Adaptation of the Glucocorticoid Toxicity Index-Metabolic Domains Instrument to Evaluate Glucocorticoid Toxicity in Adults with Myasthenia Gravis using Electronic Health Records in the United States
• Comorbidities in Myasthenia Gravis in the US National Veterans Affairs Health Network
• Impact of Glucocorticoid Use on Mortality in Adults with Chronic Diseases: A Systematic Literature Review

Poster

• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part A of ADAPT NXT
• Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
• Analysis of Serious Infections and Malignancy Risk in Myasthenia Gravis: A US Claims Database Study
• Achievement of Minimal Symptom Expression and Effect on Disease-Specific Measures in Acetylcholine Receptor Antibody-Positive Participants With Generalized Myasthenia Gravis Treated With Efgartigimod in ADAPT/ADAPT+
• Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) in Canada
• Overview of the Safety Profile of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases

Poster

• efgartigimod Prevents Necrosis And Allows For Muscle Fiber Regeneration In A Humanized Mouse Model Of Immune-Mediated Necrotizing Myopathy

Poster

• Long-Term Safety, Tolerability, and Efficacy of Efgartigimod in Participants With Generalized Myasthenia Gravis: Concluding Analyses From ADAPT+

Posters

• LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CONCLUDING ANALYSES FROM THE ADAPT+ STUDY
• DOSE SELECTION AND CLINICAL DEVELOPMENT OF EFGARTIGIMOD PH20 SUBCUTANEOUS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
• LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT-SC+ STUDY
• LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM ANALYSIS OF ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY SERONEGATIVE PARTICIPANTS IN THE ADAPT-SC+ STUDY
• A CASE OF TREATMENT WITH EFGARTIGIMOD IN A PATIENT WITH GENERALIZED MYASTHENIA GRAVIS AND LRP4 ANTIBODIES
• TREATMENT-RELATED INEQUITIES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FACING SOCIAL DETERMINANTS OF HEALTH CHALLENGES: A SURVEY OF NEUROLOGISTS IN THE UNITED STATES
• DIAGNOSTIC INEQUITIES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS FACING SOCIAL DETERMINANTS OF HEALTH CHALLENGES: A SURVEY OF NEUROLOGISTS IN THE UNITED STATES
• EFGARTIGIMOD IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP): FINAL RESULTS FROM THE ADHERE TRIAL
• OVERVIEW OF THE SAFETY PROFILE FROM EFGARTIGIMOD CLINICAL TRIALS IN PARTICIPANTS WITH DIVERSE IGG-MEDIATED AUTOIMMUNE DISEASES

Posters

• HUMORAL IMMUNE RESPONSE TO POLYVALENT PNEUMOCOCCAL VACCINE IN HEALTHY PARTICIPANTS RECEIVING EFGARTIGIMOD
• SUBCUTANEOUS EFGARTIGIMOD PH20 TREATMENT IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS IN ADAPT-SC+: INTERIM ANALYSES ON QUALITY OF LIFE, EFFICACY, TOLERABILITY, AND LONG-TERM SAFETY
• REAL-WORLD OUTCOMES OF PATIENTS LIVING WITH GENERALIZED MYASTHENIA GRAVIS INITIATING EFGARTIGIMOD TREATMENT IN THE UNITED STATES
• RACIAL DISPARITIES IN ACUTE CARE UTILIZATION OUTCOMES AMONG THOSE WITH MYASTHENIA GRAVIS
• NETWORK META ANALYSIS OF TREATMENT OPTIONS IN GENERALIZED MYASTHENIA GRAVIS: IMPACT ON HEALTH-RELATED QUALITY OF LIFE
• ASSOCIATION BETWEEN PATIENT SUPPORT PROGRAM PARTICIPATION AND ACCESS TO EFGARTIGIMOD TREATMENT FOR GENERALIZED MYASTHENIA GRAVIS
• REAL-WORLD BURDEN ASSOCIATED WITH SOCIAL DETERMINANTS OF HEALTH CHALLENGES FOR INDIVIDUALS LIVING WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
• ACHIEVEMENT OF MINIMAL SYMPTOM EXPRESSION IN ACETYLCHOLINE-RECEPTOR ANTIBODY-POSITIVE PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS AND EFFECT ON DISEASE-SPECIFIC MEASURES IN ADAPT/ADAPT+ STUDIES

Poster

• Comparison of patient identification methodologies in chronic inflammatory demyelinating polyneuropathy using United States administrative claims data
• Burden of illness for adults with chronic inflammatory demyelinating polyneuropathy in the United States
• Real-world treatment patterns in adults with chronic inflammatory demyelinating polyneuropathy in the United States
• Validation of treatment patterns in adults with chronic inflammatory demyelinating polyneuropathy in the United States using administrative claims datasets

Posters

• Efgartigimod: Clinical Development of an FcRn Antagonist for Treatment of IgG-Mediated Autoimmune Neurological Diseases

Poster

• Evidence gap analysis of the burden of illness and treatment of thyroid eye disease

Poster

• Clinical Outcomes, Disease Course, and Health-Related Quality of Life in PatientsWith Multifocal Motor Neuropathy: iMMersioN, Study in Progress

Poster

• Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: Results of ADHERE/ADHERE+
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis

Poster

• Clinical Outcomes Disease Course and QoL in Patients With Multifocal Motor Neuropathy iMMersioN Study in Progress
• Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Chronic Inflammatory Demyelinating Polyneuropathy Results of ADHEREADHERE+
• Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy_Initial Safety and Efficacy Data of the Phase 2 ARDA Study
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis_Part A of ADAPT NXT
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Tapering of Corticosteroids in Patients With Generalized Myasthenia Gravis Treated With Efgartigimod A Case Series

• Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
• Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Adm
• Efficacy, Safety, and Pharmacodynamics of Efgartigimod PH20 SC Across Bodyweight Quartiles A Post hoc Analysis of the ADAPT-SC+ Trial
• Exploring the Impact of Nonsteroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients With Myasthenia Gravis
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
• Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
• Patterns Of Efgartigimod Dosing In Clinical Practice In The United States
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Quality Of Life of Patients with Symptomatic Ocular MG Comparison with the General Population
• Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
• Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States

Poster

• Clinical Outcomes, Disease Course, and Quality of Life in Patients With MultifocalMotor Neuropathy iMMersioN, Study in Progress
• Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
• COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
• Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial Subgroup Analysis
• Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHEREADHERE+ Trials
• Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy Initial Safety and Efficacy Data of the Phase 2 ARDA Study
• Empasiprubart(ARGX-117) in Multifocal Motor Neuropathy Baseline Characteristics and MMN Confirmation Committee Outcomes of the Phase 2 ARDA Stud
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
• Heterogeneity of EQ-5D-5L utilities among people suffering from CIDP
• Long-Term Safety and Efficacy of Efgartigimod PH20 SC in Generalized Myasthenia Gravis Interim Analysis of Anti-Acetylcholine Receptor Antibody
• Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis Interim Result
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
• Risk of Serious Infections and Malignancies in Adult Myasthenia Gravis Patients A US Claims Database Study
• Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
• Safety Profile of Subcutaneous Efgartigimod PH20 From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
• Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients With Amyotrophic Lateral Sclerosis A Phase 2a Study
• Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes Phase
• Steroid Toxicity in Adults With Myasthenia Gravis in the United States Based on Electronic Health Records
• Steroid Use, Toxicity, and Monitoring in Patients With Chronic Inflammatory Demyelinating Polyneuropathy A Survey of Neurologists in the United
• Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States
• Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy Key Secondary Outcomes From the ADHERE Trial
• The Burden people suffering from CIDP experience In terms of Utilities Comparison With The General Population